Microbix and EMQN Launch Genetic Testing Initiative

Microbix Biosystms (TSE:MBX) has released an update.

Microbix Biosystems has teamed up with EMQN to launch a novel genetic-test program aimed at identifying patients susceptible to antibiotic-induced hearing loss. This initiative, which utilizes Microbix’s quality assessment products, is crucial for ensuring accurate diagnoses and effective treatment plans, particularly for newborns at risk of severe infections.

For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.